Britain and America have secured a major trade agreement that will maintain zero levies on UK pharmaceutical products being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to increase funding on pharmaceuticals through the NHS. This commitment guarantees that duties on these crucial products will remain at nothing for a period of the next three years.
This agreement is in response to recent threats to significantly raise tariffs on patented pharmaceutical products, with figures discussed up to 100%.
"This agreement between the Britain strengthens the international landscape for new treatments and brings much-needed balance to transatlantic medicine commerce," an announcement noted.
Commercial Impact
Drugs constitute one of the the United Kingdom's largest exports to the United States, which is by far the largest market for large companies like GSK and AstraZeneca.
Trade data reveal that in the year to the end of last September, the UK exported medicines totaling billions to the US. This figure represented 17.4% of total UK exports in that timeframe.
"This agreement protects work, increases investment and paves the way for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary commented.
Specific UK Commitments
The pact entails several key commitments from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to double total NHS spending on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The percentage drug companies must return to the NHS to prevent overspending will be restricted at fifteen percent. Last year, repayments were more than 20%.
Industry Background
The pact takes place against a ongoing tension between the pharmaceutical industry and the UK government over spending levels and regulatory access.
The disagreement were exacerbated by arguments that American consumers were paying significantly more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been delayed or cancelled, while major funding commitments have been directed toward American operations.
A senior figure stated that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had declined as a share of its resources over the previous ten-year period.
